BNP Paribas Financial Markets’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $94 | Hold |
40
| – | – | ﹤0.01% | 5689 |
|
|
2025
Q4 | $93 | Hold |
40
| – | – | ﹤0.01% | 5619 |
|
|
2025
Q3 | $75 | Hold |
40
| – | – | ﹤0.01% | 5453 |
|
|
2025
Q2 | $116 | Buy |
40
+28
| +233% | +$40 | ﹤0.01% | 5320 |
|
|
2025
Q1 | $9 | Hold |
12
| – | – | ﹤0.01% | 5341 |
|
|
2024
Q4 | $12 | Hold |
12
| – | – | ﹤0.01% | 5358 |
|
|
2024
Q3 | $16 | Hold |
12
| – | – | ﹤0.01% | 4109 |
|
|
2024
Q2 | $16 | Hold |
12
| – | – | ﹤0.01% | 4015 |
|
|
2024
Q1 | $21 | Hold |
12
| – | – | ﹤0.01% | 3999 |
|
|
2023
Q4 | $18 | Hold |
12
| – | – | ﹤0.01% | 3980 |
|
|
2023
Q3 | $15 | Buy |
+12
| New | +$17 | ﹤0.01% | 3886 |
|
|
2023
Q1 | – | Sell |
-668
| Closed | -$1.16K | – | 4040 |
|
|
2022
Q4 | $1.16K | Buy |
668
+146
| +28% | +$273 | ﹤0.01% | 3786 |
|
|
2022
Q3 | $1.04K | Sell |
522
-26,654
| -98% | -$26.5K | ﹤0.01% | 4424 |
|
|
2022
Q2 | $20.1K | Buy |
27,176
+24,668
| +984% | +$71.7K | ﹤0.01% | 3694 |
|
|
2022
Q1 | $21.8K | Sell |
2,508
-6,489
| -72% | -$66.5K | ﹤0.01% | 3712 |
|
|
2021
Q4 | $144K | Buy |
8,997
+4,654
| +107% | +$73.9K | ﹤0.01% | 3490 |
|
|
2021
Q3 | $80K | Buy |
4,343
+3,396
| +359% | +$54.5K | ﹤0.01% | 3363 |
|
|
2021
Q2 | $13.2K | Sell |
947
-13,382
| -93% | -$187K | ﹤0.01% | 3653 |
|
|
2021
Q1 | $211K | Buy |
14,329
+10,535
| +278% | +$185K | ﹤0.01% | 3020 |
|
|
2020
Q4 | $73.6K | Buy |
3,794
+473
| +14% | +$7.37K | ﹤0.01% | 3367 |
|
|
2020
Q3 | $37.1K | Buy |
3,321
+2,871
| +638% | +$34K | ﹤0.01% | 3600 |
|
|
2020
Q2 | $6.09K | Sell |
450
-3,384
| -88% | -$38K | ﹤0.01% | 3919 |
|
|
2020
Q1 | $31K | Buy |
3,834
+1,042
| +37% | +$9.19K | ﹤0.01% | 3764 |
|
|
2019
Q4 | $26.8K | Buy |
2,792
+1,353
| +94% | +$14.6K | ﹤0.01% | 3920 |
|
|
2019
Q3 | $15.3K | Buy |
1,439
+8
| +0.6% | +$84 | ﹤0.01% | 4055 |
|
|
2019
Q2 | $16.5K | Sell |
1,431
-276
| -16% | -$3.32K | ﹤0.01% | 3964 |
|
|
2019
Q1 | $21.9K | Buy |
1,707
+1,341
| +366% | +$14.2K | ﹤0.01% | 3879 |
|
|
2018
Q4 | $2.25K | Buy |
366
+145
| +66% | +$1.17K | ﹤0.01% | 3779 |
|
|
2018
Q3 | $2.32K | Sell |
221
-13
| -6% | -$151 | ﹤0.01% | 4242 |
|
|
2018
Q2 | $3.43K | Sell |
234
-827
| -78% | -$10.6K | ﹤0.01% | 4185 |
|
|
2018
Q1 | $15.1K | Sell |
1,061
-182
| -15% | -$2.21K | ﹤0.01% | 3965 |
|
|
2017
Q4 | $14.6K | Buy |
+1,243
| New | +$15.3K | ﹤0.01% | 3999 |
|
Other funds holding SPRO
GP
P
VCM
AI
AFM
BNP Paribas Financial Markets's SPRO Position: Q1 2026 in Review
BNP Paribas Financial Markets held its Spero Therapeutics (SPRO) position steady in Q1 2026 at 40 shares worth $94. The position accounts for ﹤0.01% of the portfolio, ranked #5689.
BNP Paribas Financial Markets first reported a position in SPRO in Q4 2017 and has held it in 32 quarters since. The position peaked at $211K in Q1 2021. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.
- BNP Paribas Financial Markets held 40 shares of Spero Therapeutics worth $94 as of Q1 2026.
- BNP Paribas Financial Markets left its Spero Therapeutics share count unchanged in Q1 2026.
- Spero Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5689 holding.
- BNP Paribas Financial Markets first reported a position in Spero Therapeutics in Q4 2017 and has held it in 32 quarters since.
- BNP Paribas Financial Markets's Spero Therapeutics position peaked at $211K in Q1 2021.
- 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.